Literature DB >> 25995438

The Myb-p300 Interaction Is a Novel Molecular Pharmacologic Target.

Xi Liu1, Kathryn A Gold1, Ethan Dmitrovsky2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25995438      PMCID： PMC4599702          DOI： 10.1158/1535-7163.MCT-15-0271

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  27 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Autodisplay: efficient bacterial surface display of recombinant proteins.

Authors:  Joachim Jose
Journal:  Appl Microbiol Biotechnol       Date:  2005-12-20       Impact factor: 4.813

Review 3.  MYB function in normal and cancer cells.

Authors:  Robert G Ramsay; Thomas J Gonda
Journal:  Nat Rev Cancer       Date:  2008-07       Impact factor: 60.716

4.  Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb.

Authors:  F Liu; W Lei; J P O'Rourke; S A Ness
Journal:  Oncogene       Date:  2006-02-02       Impact factor: 9.867

5.  Inhibition of Myb-dependent gene expression by the sesquiterpene lactone mexicanin-I.

Authors:  T Bujnicki; C Wilczek; C Schomburg; F Feldmann; P Schlenke; C Müller-Tidow; T J Schmidt; K-H Klempnauer
Journal:  Leukemia       Date:  2011-10-11       Impact factor: 11.528

Review 6.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

7.  Identification of small-molecule antagonists that inhibit an activator: coactivator interaction.

Authors:  Jennifer L Best; Carlos A Amezcua; Bernhard Mayr; Lawrence Flechner; Christopher M Murawsky; Beverly Emerson; Tsaffrir Zor; Kevin H Gardner; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-07       Impact factor: 11.205

Review 8.  How can oncogenic transcription factors cause cancer: a critical review of the myb story.

Authors:  M Introna; J Golay
Journal:  Leukemia       Date:  1999-09       Impact factor: 11.528

9.  Positive and negative determinants of target gene specificity in myb transcription factors.

Authors:  Wanli Lei; John J Rushton; Lisa M Davis; Fan Liu; Scott A Ness
Journal:  J Biol Chem       Date:  2004-04-21       Impact factor: 5.157

10.  c-Myb is required for progenitor cell homeostasis in colonic crypts.

Authors:  Jordane Malaterre; Marina Carpinelli; Matthias Ernst; Warren Alexander; Michael Cooke; Susan Sutton; Sebastian Dworkin; Joan K Heath; Jon Frampton; Grant McArthur; Hans Clevers; Douglas Hilton; Theo Mantamadiotis; Robert G Ramsay
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205
View more
  2 in total

Review 1.  Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Patrizia Porazzi; Marco De Dominici; Joseph Salvino; Bruno Calabretta
Journal:  Genes (Basel)       Date:  2021-08-29       Impact factor: 4.096

2.  Rational design of a helical peptide inhibitor targeting c-Myb-KIX interaction.

Authors:  Shunji Suetaka; Yoshiki Oka; Tomoko Kunihara; Yuuki Hayashi; Munehito Arai
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.